Janux Therapeutics is now rated Hold after recent JANX007 Phase 1 data failed to show clear differentiation in mCRPC. JANX007 demonstrates strong PSA reductions but limited radiographic partial ...
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback